New Advances in Cell Microarray Technology to Expand Applications in Target Deconvolution and Off-Target Screening

Identifying the cell surface receptors of natural ligands, and deconvoluting the receptor targets of candidate drug leads, presents a challenge in medical research and drug discovery. Traditionally, success rates have been low, and screening efforts often generate numerous false-positive hits that require extensive follow-up to either validate or disregard. If successful, receptor identification enables the discovery of previously unknown, disease-relevant targets, provides critical insights into biological pathways and disease processes, and allows for secondary targets to be uncovered. By expressing the majority of the human plasma membrane proteome in human cells on glass slides in situ, human cell microarray technology provides a powerful approach for identifying receptor target interactions. This approach significantly increases the success rates in identifying specific primary receptor targets and off-targets while limiting the number of false-positive hits. Here we describe cell microarray technology, focusing on new advances including the use of whole cells as bait for receptor interactions, and the inclusion of secreted proteins that widens the utility of the technology in off-target screening.

[1]  Anil Vasudevan,et al.  Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective. , 2018, Journal of medicinal chemistry.

[2]  Joseph D. Smith,et al.  Severe malaria is associated with parasite binding to endothelial protein C receptor , 2013, Nature.

[3]  R. Minter,et al.  Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling , 2015, Molecular Cancer.

[4]  K. Green,et al.  Identification of Human Junctional Adhesion Molecule 1 as a Functional Receptor for the Hom-1 Calicivirus on Human Cells , 2017, mBio.

[5]  A. Wiestner,et al.  Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies , 2018, Cancer Immunology Research.

[6]  M. Fallahi,et al.  Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. , 2017, Journal of molecular biology.

[7]  M. Dennis,et al.  Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 , 2011, mAbs.

[8]  P. Sorensen,et al.  Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. , 2015, Cancer cell.

[9]  R. Minter,et al.  Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy , 2016, Oncotarget.

[10]  T. Cash-Mason,et al.  GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.

[11]  Bing-he Xu,et al.  Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study , 2018, British Journal of Cancer.

[12]  K. S. Johnson,et al.  Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement , 2018, mAbs.